Warfarin is the main anticoagulant therapy in the prevention of thromboembolism in patients with atrial fibrillation or mechanical valve. The significant number of patients referred for coronary angiography (CAG) is receiving warfarin. The standard recommendation for these patients is to discontinue warfarin before CAG in high thromboembolism risk with keeping international normalized ratio level (INR) to the optimized target level, that is, less than 1.8. 1 Either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) is often administered as bridging therapy around the time of procedure. 2, 3 There are several disadvantages of bridging with heparin in the perioperative period, including the extended hospital stays, the expense, the inconvenience of heparin administration, and potential thromboembolism associated with subtherapeutic anticoagulation. [4] [5] [6] In addition, the bridging therapy with heparin after procedure until the desired target level of INR is reached may lead to increased risk of postprocedural bleeding. [7] [8] [9] With this regard, the periprocedural strategy for anticoagulation management is a considerable challenge in which the risks of periprocedural hemorrhage and thromboembolism must be balanced. 3 Previous studies have demonstrated that it is safe to perform pacemaker/defibrillator placement surgery 8 and ablation of atrial flutter-fibrillation without interrupting the warfarin treatment. [10] [11] [12] Similarly, several reports have suggested that coronary angiography may be safely performed when oral anticoagulant therapy was continued. 13 It has also been suggested that the bridging therapy may lead to increased risk of access site complications after percutaneous coronary intervention (PCI).
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The radial artery access has less vascular complications than the femoral approach. With this regard, the international guidelines have recommended radial access as a preferred approach in patients with high-risk bleeding. 1, 3, 20 Nevertheless, the radial access takes longer procedural time and higher radiation exposure. 21 In addition, the femoral access is still warranted in some patients whom radial route is not accessible.
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The data from randomized-controlled studies comparing the safety of heparin bridging and uninterrupted warfarin in patients undergoing transfemoral CAG are lacking. The aim of our study was to assess the safety of elective transfemoral CAG during uninterrupted warfarin therapy as compared to the traditional bridging heparin therapy, in terms of vascular access site complications.
| METHODS
The 
| Statistical analysis

| RESULTS
Demographic data and procedural features are presented in Table 1 .
From January 2014 to December 2015, 110 consecutive patients who met the inclusion criteria were randomly divided to uninterrupted warfarin group (n = 55) or bridging heparin group (n = 55). Baseline characteristics of patients between the two treatment groups were comparable in terms of age, gender, underlying diseases and procedural features (Table 1 ). All patients had underlying valvular diseases, mostly rheumatic heart diseases. Nearly all patients had atrial fibrillation. Expectedly, the mean pre-procedural INR level was significantly higher in uninterrupted warfarin group than conventional group (2.2 ± 0.5 vs 1.2 ± 0.3, P < 0.001).
The incidence of vascular access site complication is shown in Table 2 . There were 3 (5.5%) cases of significant groin hematoma (≥5 cm) observed in heparin bridging group. One of them had groin hematoma with pseudoaneurysm which required ultrasound-guided compression therapy. No major vascular access site complications occurred in uninterrupted warfarin group. Incidence of total vascular access site complications was non-significantly lower in uninterrupted warfarin than heparin bridging groups (1.8% vs 10.9%, P = 0.113) (Fig. 1) . A small hematoma at vascular access site (<5 cm) was noted in one case from uninterrupted warfarin group and three cases in heparin bridging group. There was no bleeding at other sites apart from the vascular access site. We found that the pre-procedure INR was inversely associated with the vascular access complications. The patients who developed large hematoma at vascular access site had lower pre-procedural INR than those who did not have large hematoma (1.1 ± 0.1 vs 1.7 ± 0.6, P = 0.044). There were only 4 of 110 patients taking aspirin in our study. We did not find any association between bleeding event and aspirin therapy in our studied population.
In addition, no thromboembolic events occurred in either group during 7 days after CAG. The length of hospital stay was similar between uninterrupted warfarin and heparin bridging groups (7.5 ± 7.1 vs 8.0 ± 4.7, P = 0.616). The results from our study were in accordance with those from other studies. [13] [14] [15] [16] [17] [18] [19] Only one small randomized controlled trial comparing heparin bridging and uninterrupted warfarin in patients undergoing transfemoral CAG has been previously reported. The investigators have demonstrated a low incidence of small hematomas with both strategy and no major vascular complications was observed in the studied population. 13 Other non-randomized studies have also shown the similar incidence of the access site complications in patients undergoing CAG between the uninterrupted warfarin group and the interrupted warfarin group with or without bridging therapy. [14] [15] [16] [17] [18] [19] Furthermore, several studies have shown that the incidence of bleeding or thrombotic complications was found not related to the periprocedural INR levels. [23] [24] [25] Of note, we found that pre-procedural INR was lower in those with vascular access site complications than those without. Our result could be explained by the fact that all patients who had large hematoma at vascular access site were in the heparin bridging group. Therefore, the pre-procedural INR after warfarin interruption was expected to be lower than that during warfarin continuation.
It has also been suggested that the heparin bridging strategy may lead to the increased risk of access site complications after PCI. On the other hand, uninterrupted warfarin with therapeutic INR (2.1-4.8)
during procedure led to the lowest event rate with no increase in bleeding events in 530 patients undergoing balloon angioplasty through the femoral route when compared to heparin bridging therapy. [23] [24] [25] Performing CAG without interrupting warfarin has several theoretical advantages. 
| LIMITATIONS
Due to the relatively small size of studied population, the results of the present study should be interpreted with caution. A total sample size of at least 280 patients would provide 80% power to detect this difference with an α-level of 0.05. Therefore, larger population is warranted to confirm our findings. 
